Intrinsic Therapeutics, Inc. Announces That ISASS Has Issued Updated 2025 Recommendations and Coverage Criteria for Barricaid Bone-Anchored Annular Closure

Barricaid is a proprietary technology designed to prevent reherniation and reoperation in patients with large annular defects following lumbar discectomy surgery. (PRNewsfoto/Intrinsic Therapeutics, Inc.)

BOSTON, June 19, 2025 /PRNewswire/ -- Intrinsic Therapeutics, a medical technology company committed to redefining the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81%* with its Barricaid Annular Closure Device, announced today that the International Society for the Advancement of Spine Surgery (ISASS) has issued a 2025 policy update on the use of bone-anchored annular closure to prevent reherniation in high-risk discectomy patients. The update reaffirms the society's recommendations and coverage criteria for medical necessity of bone-anchored annular closure for patients undergoing discectomy with large annular defects in order to sustain the treatment benefits of discectomy.

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us.

Thank you for reading!

Please log in, or sign up for a new account to continue reading.